BIOGNOSYS
14.12.2021 16:02:08 CET | Business Wire | Press release
Biognosys, a leading developer and provider of next-generation proteomics technology and solutions, and Thermo Fisher Scientific, the world leader in serving science with innovative technologies, purchasing convenience and pharmaceutical services, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.
The agreement leverages the two companies’ complementary capabilities in mass spectrometry-based proteomics. Biognosys deploys Thermo Fisher Scientific instruments in its state-of-the-art facility for contract research services, while Thermo Fisher Scientific co-markets Biognosys software and kits with its Thermo Scientific™ instruments and workflows.
Biognosys’ Biomarker Discovery services for pharmaceuticals and diagnostics development integrate Thermo Scientific Orbitrap™ and FAIMS Pro™ instruments with Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and Spectronaut™ Data Independent Acquisition (DIA) analysis software to offer unprecedented depth, quantitative precision, and throughput for unbiased discovery. This new and improved solution searches the complete proteome to quantify up to 3,000 of the most relevant proteins in biofluids and more than 10,000 proteins in tissue biopsies.
Andreas Huhmer, PhD, Senior Director Life Sciences Research OMICS Marketing at Thermo Fisher Scientific: “Biognosys’ Biomarker Discovery solutions maximize all innovative features of the Thermo Scientific Orbitrap mass spectrometers to analyze the proteome with industry-leading depth. Their unbiased discovery approach, coupled with their state-of-the-art data analysis capabilities, unlocks possibilities for transformative biomarker discovery.”
Through the companies’ extended co-marketing agreement , laboratories with in-house proteomics facilities have access to efficient, accurate, and scalable mass spectrometry-based proteomics workflows combining Thermo Scientific mass spectrometry instruments with Biognosys’ proteomics data analysis software and kits.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys: “Our agreement with Thermo Fisher Scientific has helped to greatly advance Biognosys’ mission to give researchers a look at every angle of the proteome to unlock discoveries and transform clinical research. Our suite of software and kits uniquely complements Thermo Scientific mass spectrometry instruments and workflows to enable researchers to obtain the best possible data and insights in any proteomics application.”
Biognosys’ leading DIA software solution, Spectronaut, is compatible with Thermo Scientific Orbitrap Exploris™ 480 and Thermo Scientific™ Q Exactive™ instruments.
Biognosys’ SpectroDive™ software for automated mass spectrometry method set-up, signal processing, and analysis of targeted proteomics experiments supports the SureQuant IS-PRM targeted acquisition workflow.
The PQ500™ Reference Peptide Kit from Biognosys can quantify more than 500 proteins in human plasma/serum samples as part of the SureQuant IS-PRM workflow with the Orbitrap Exploris™ 480 mass spectrometer, delivering sensitive and accurate quantitation to drive scientific progress or clinical decision making.
Learn more about the insights that can be uncovered through the Biognosys and Thermo Fisher Scientific partnership from Lukas Reiter’s presentation, “Recent Progress in Blood Proteomics” , during the Thermo Fisher Scientific dinner workshop at ASMS 2021.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Successfully Prices €650 million of SPACE Hybrid Securities17.3.2026 23:00:00 CET | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT)) OR IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (SEE “OFFER AND DISTRIBUTION RESTRICTIONS” BELOW). SES Financing S.à r.l., a wholly owned subsidiary of SES, announced the successful launch and pricing of the PNC5.25 Subordinated Perpetual with Automatic Conversion Events (“SPACE”) hybrid transaction, guaranteed on a subordinated basis by SES and SES Americom. SES Financing S.à r.l. is rated Ba1 (stable) and BBB- (stable) by
Rimini Street Announces Participation in the ROTH Capital Partners 38th Annual Investor Conference17.3.2026 22:37:00 CET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the following upcoming ROTH Capital Partners Investor Conference, March 23 and 24, 2026, in Laguna Niguel, California: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317799301/en/ Rimini Street Announces Participation in the ROTH Capital Partners 38th Annual Investor ConferenceSeth Ravin, CEO, and Dean Pohl, vice president, treasurer and investor relations, will participate in one-on-one and small group meetings (Seth Ravin, March 23 only) Seth Ravin will participate in a panel discussion led by ROTH Capital Partners Managing Director, Senior Research Analyst Rich Baldry, titled “Software: Risks, Opportunities & Realities of the AI Emergence” on March 23, 2:00 p.m. – 2:55 p
The World Goes Green for St Patrick’s Day 202617.3.2026 17:50:00 CET | Press release
Ireland Leads a Global Celebration of Culture and Community This March, St Patrick’s Day invites people all over the world to become Irish for a day, as cities and communities across the globe unite in a shared celebration of heritage, culture and connection. From parades and parties to the famous global greenings, the festival’s spirit reaches far beyond Ireland’s shores. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260306890851/en/ St Patrick's Festival Kilkenny City 2022 The World Goes Green Ireland’s national holiday, St Patrick’s Day unites a global community in a vivid moment of celebration. Each year, hundreds of iconic landmarks are illuminated in green, from the Empire State Building in New York and the Leaning Tower of Pisa in Italy to Niagara Falls in Canada and the Wallace Monument in Scotland. These striking displays reflect the far-reaching connections of Irish communities overseas and the worldwide affection
USD 1.63 Billion In 72 Hours: Manchester City Yas Residences by Ohana Development Sets New Sales Record In Abu Dhabi17.3.2026 16:44:00 CET | Press release
• 35% of investors are Emiratis, while 65% are expatriates and international investors • Milestone reflects strong demand for the project and continued confidence in the UAE’s real estate sector Ohana Development, a leading UAE real estate developer renowned for its luxury projects, has recorded USD 1.63 billion in sales within 72 hours for Manchester City Yas Residences by Ohana, a gated waterfront community located along Yas Canal in Abu Dhabi, setting a new sales record in the emirate’s real estate market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317595867/en/ Manchester City Yas Residences by Ohana (Photo: AETOSWire) Investors queued at the sales launch, reflecting the strong demand for the project. Of the investors, 35% are Emiratis, while 65% are expatriates and international buyers. In response to this significant interest, Ohana Development is expected to release additional inventory from the project soon. I
Speech Processing Solutions Launches Philips SpeechLive Health, an AI Assistant Built for Modern Clinical Documentation17.3.2026 15:00:00 CET | Press release
Philips SpeechLive Health AI Assistant uses healthcare-trained AI to convert clinical conversations into structured notes, helping clinicians reduce administrative burden Speech Processing Solutions, the global leader in professional dictation and speech solutions sold under the Philips brand, today announced the upcoming April 2026 launch of Philips SpeechLive Health AI Assistant, an AI-powered clinical documentation assistant designed for healthcare professionals across multiple care settings. This solution reduces administrative burden, streamlines documentation, and improves provider and patient experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317743584/en/ Philips SpeechLive Health AI Assistant turns clinical conversations into structured documentation, helping reduce administrative workload and create more time for patient care. Purpose-built for clinical documentation workflows Clinical workload remains
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom